A comparison of the results from the proving of Erythrina lysistemon 30CH, with toxicology of the crude substance
The homoeopathic drug proving of Erythrina lysistemon 30CH took a form of a randomised triple–blind, placebo–controlled study. This trial was conducted at the Homoeopathic Day Clinic on the premises of Durban University of Technology. The research group consisted of 32 provers, which were recruited from amongst practicing homoeopaths, homoeopathic students (2`nd–5`th year), as well as patients of the Homoeopathic Day Clinic (DUT) and their relatives. The participation was purely on voluntary basis. Provers were randomly divided into two groups: a placebo group of 12; a proving group of 20. Each researcher supervised 8 provers. Neither the provers, nor the researchers were aware of the name or nature of the substance being proved, and whether a prover is receiving a placebo or the proving substance until the unblinding process. Provers had a homoeopathic case history taken and a physical examination performed on them before commencement of the proving to establish each individual’s baseline. Provers were required to keep journals in which they recorded their sign and symptoms: starting 7 days prior to commencing the proving, throughout the proving, as well as after administration of the remedy formulated. All the information gathered was then correlated and interpreted by the researchers i.e. four M.Tech.Hom students. Subsequent translation of the symptoms into materia medica and repertory language took place. On completion of the proving a homoeopathic picture of the remedy with III distinct affinities was established. Those affinities were then compared to the toxicology of the major chemical constituents of Erythrina lysistemon. Data was then analyzed by qualitative methods for it was not amendable to standard statistical analysis.